Agoracom Blog Home

Posts Tagged ‘CSE’

« Older Entries
Newer Entries »

Tetra Bio-Pharma Signs LOI with Constance Therapeutics TBP.ca

Posted by AGORACOM-JC at 9:52 AM on Wednesday, July 19th, 2017

Tbp large new

  • Signed a Letter of Intent (LOI) with Constance Therapeutics,
  • Clinical development and commercialization in Canada of its signature standardized, patent-pending, medicinal cannabis extract products
  • AgroTek Health subsidiary of Tetra will work with Constance Therapeutics to bring these products to the Canadian medical marijuana market

OTTAWA, ONTARIO–(July 19, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today it has signed a Letter of Intent (LOI) with Constance Therapeutics, Inc. of San Francisco, California, USA, for the clinical development and commercialization in Canada of its signature standardized, patent-pending, medicinal cannabis extract products.

The AgroTek Health subsidiary of Tetra will work with Constance Therapeutics to bring these products to the Canadian medical marijuana market under a commercial license agreement. “Over the coming months, the corporation will be focusing its energy on generating revenues while becoming an important player in the medical marijuana market,” commented Mr. Andre Rancourt, CEO of Tetra. “The products developed by Constance Therapeutics are exactly what the corporation is looking for in terms of novel cannabis products developed for patients. The approach used by Constance Therapeutics is exactly the type of business model that Tetra is implementing to bring medical marijuana products to patients.”

“Constance Therapeutics works in conjunction with physicians and medical professionals to provide integrative medicinal options to those suffering from serious conditions, such as cancer, lyme, auto-immune, chronic pain, neurodegenerative diseases, and other out-of-option patients,” commented Constance Finley, Founder and CEO of Constance Therapeutics, Inc. She added, “over the years, research demonstrates that cannabinoids including specific terpenes, reduce and inhibit tumor growth in various animal models. Early clinical studies suggest cannabinoids enhance the effects of traditional cancer treatments with radiation therapy and help reduce the size of brain cancers, such as Glioma, compared to controls.”

Tetra will enter into a licensing agreement with Constance Therapeutics to perform clinical research on the novel cannabis extract products initially focusing on their use in treating patients with brain cancer. Tetra will work closely with oncologists to evaluate the therapeutic benefit of these products according to pharmaceutical standards.

These products are currently available to patients living in California, USA and are consumed sublingually and through vaporization. As part of its mission to bring effective cannabinoid-based products to cancer patients, Tetra will be working in partnership with Constance Therapeutics to investigate the potential efficacy in a clinical trial.

About Constance Therapeutics:

Constance Therapeutics, Inc. is a manufacturer and licensor of cannabis products designed to enable medical professionals offer their patients a broader array of treatment options. The products fill the gap between traditional pharmaceuticals and commonplace cannabis products through manufacturing protocols using highly controlled, quantitatively-defined and patented processes. The products are third-party tested in the industry’s most respected laboratories. Since 2008, the company has employed stringent, science-based processes and standards to ensure the highest quality and consistency. Headquartered in San Francisco, California, Constance Therapeutics’ products have historically been accessed exclusively for therapeutic use and could only be purchased by registered California patients, in keeping with Proposition 215, and California Senate Bill 420. For further information, visit: www.constancetherapeutics.com.

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
[email protected]

Tags: , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma Signs LOI with Constance Therapeutics TBP.ca

Marijuana Company of America Receives Financing for JV in Washington State $MCOA.us

Posted by AGORACOM-JC at 9:41 AM on Wednesday, July 19th, 2017

15233 mcoa

  • Contributed the first installment of capital to Bougainville Ventures, Inc. in partial satisfaction of the joint venture agreement entered into earlier this year in Washington State
  • MCOA received $375,000 in its first round of financing
  • Investment will contribute to funding the development of a state-of-the-art 30,000 sq. ft. greenhouse grow facility in Oroville, Washington

ESCONDIDO, CA–(Jul 19, 2017) – MARIJUANA COMPANY OF AMERICA INC. (“MCOA” or the “Company”) (OTC: MCOA), an innovative cannabis and hemp marketing and distribution Company, is pleased to announce that it has contributed the first installment of capital to Bougainville Ventures, Inc. (“BV”) in partial satisfaction of the joint venture agreement entered into earlier this year in Washington State.

MCOA received $375,000 in its first round of financing. This investment will contribute to funding the development of a state-of-the-art 30,000 sq. ft. greenhouse grow facility in Oroville, Washington. Once completed, the greenhouse facility will accommodate a cannabis production and processing tenant with a Tier 3, I-502 license with significant experience growing cannabis. The total principal amount of the convertible note that MCOA executed with its financing partner is $752,500, with a 16 month term and 10% annual interest rate. Additional rounds of financing will be received as part of this note, which MCOA intends to invest in BV in satisfaction of the terms of its JV agreement.

As turnkey landlords, MCOA and BV look to provide an ideal cultivation environment that their current tenant can move into in Q3, and be fully operational and revenue producing in early Q4. As more states legalize the cultivation and consumption of cannabis, MCOA intends to replicate this business model and build the Company’s real estate portfolio and increase its revenue.

Donald Steinberg, MCOA President and CEO, said, “I am very pleased that we obtained the financing to start our operations in Washington. We are projecting that this joint venture will soon be profitable and be a model that we can replicate in other states and countries. We are also happy to establish a relationship with a financing partner that is interested in supporting joint venture projects for MCOA in the future.”

The closing of its first round of financing is a significant step in completing the Company’s JV partnership that was formed to construct two greenhouses, provide management services and a commercial lease to an I-502 licensed grower in Washington State.

Separately, the Company announced effective July 1, 2017, the establishment of a new corporate office located at 1320 West Valley Parkway, Escondido, California, 92029, that will include space for the Company’s back office support team for its HempSMART brand, and provide office space for some Company executives.

ABOUT BOUGAINILLE VENTURES, INC.
Bougainville Venture Inc. is in the core business of converting irrigated farmland that was traditionally used to grow marginally profitable feed crops, to greenhouse-equipped farmland used to grow luxury crops with a primary focus on high-density and high-yielding crops. Bougainville is an agricultural services company that focuses on providing growers with state-of-the-art computer controlled greenhouses and processing facilities. Bougainville offers fully built out turnkey solutions to tenant-growers and provides growing infrastructure, as well as landlord services for licensed I-502 producers and processors in the state of Washington.

SAFE HARBOR STATEMENT
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
[email protected]

Tags: , , ,
Posted in All Recent Posts, Medical Marijuana Stocks | Comments Off on Marijuana Company of America Receives Financing for JV in Washington State $MCOA.us

New Age Metals Commences 15,000 ft Drill Program at River Valley – Largest Underveloped PGM Project in Canada $PGM.ca

Posted by AGORACOM-JC at 9:53 AM on Tuesday, July 18th, 2017

New age large

  • Abitibi Geophysics has completed the surface IP geophysical program and borehole geophysics
  • Drilling will focus on follow-up drilling to further test the continuation of the Pine Zone
  • Further drilling will drill test the geophysical interpretation of Abitibi Geophysics
  • River Valley is the Largest Undeveloped Primary PGM resource in Canada, with 2.5 Moz PGM, in Measured Plus Indicated mineral resources and near-surface mineralization covering over 16kms of strike

Vancouver, Canada / July 18, 2017 – New Age Metals Inc. (TSX.V: NAM; OTCQB: PAWEF; FSE: P7J.F) is pleased to announce that the 2017 Drill Program has commenced on the Pine Zone at the River Valley PGM Project approximately 100km’s from Sudbury, Ontario. The Induced Polarization (IP) geophysical survey and borehole geophysics has been completed by Abitibi Geophysics and a final report will be generated. The Company will focus the exploration on drill testing the previous PGM mineralization in the Pine Zone and the recommendations from the geophysical interpretation report.

The Pine Zone is one of numerous prospective PGM zones (Figure 1) within the district-scale River Valley PGM Project and was recently drilled in the fall of 2016 (press release December 13, 2016). The 2016 drill program confirmed the higher-grade, near-surface PGM discovery made in the 2015 drill program (press release March 11, 2015) and highlighted the continuity of the mineralization for 200 metres along strike and 100-200 metres depth at the Pine Zone. The Pine Zone remains open along strike and at depth.

The surface geophysical survey was designed to test the eastward and southward extension of the Pine Zone as well as the adjacent Dana North Zone (Figure 2). The extension of the IP survey is designed to test the depth potential of the Banshee Zone. The survey will aid in the generation of new targets for follow up drill testing. The diamond drill crew is currently onsite and will begin drilling to test the on strike and depth extensions of the Pine Zone as a continuation of the 2016 drilling (press release December 13, 2016).Approximately 15,000ft of drilling is planned in this program.

Abitibi Geophysics will generate a final report and interpretation of the IP Geophysical Survey. This report will recommend additional drill targets. These targets will be on the Pine and Banshee Zones. Approximately 2 km of untested potential for discovery of additional mineralization presently exists along strike between the current drilled extent of the Pine Zone and the underexplored Pardo Zone to the northwest (Figure 2).


Click Image To View Full Size

Figure 1. Location of NAM’s 100% owned River Valley PGM Project.

This present exploration activity of drilling and geophysics is geared to establish the resource base for a Preliminary Economic Assessment (PEA) Report which the company plans to initialize in the near future.

 


Click Image To View Full Size

Figure 2. Property scale geological map showing the location of the Pine Zone discovery relative to the Dana North Zone immediately to the west and the Pardo Zone 2 km to the northeast. Note the apparent dextral sense of offset of the River Valley PGM deposit (red) across the Grenville Front Tectonic Zone.

To date an approximate 612 holes (136,574 metres) have been conducted by the company and its past joint venture partners to test the PGM mineralization extents of the River Valley Intrusion. As well, several 43-101 complaint resource estimates have been generated. The River Valley Deposit is the Largest Undeveloped Primary PGM resource in Canada, with 2.5M oz PGM, in Measured Plus Indicated mineral resources and near-surface mineralization covering over 16kms of continuous strike length.

The Company will continue to update investors as the drill results are received.

ABOUT NAM’S PGM DIVISION

NAM’s flagship project is its 100% owned River Valley PGM Project (NAM Website – River Valley Project) in the Sudbury Mining District of Northern Ontario (100 km east of Sudbury, Ontario). Presently the River Valley Project is Canada’s largest primary undeveloped PGM deposit with Measured + Indicated resources of 91 million tonnes @ 0.58 g/t* Palladium, 0.22 g/t Platinum, 0.04 g/t Gold, at a cut-off grade of 0.8 g/t for a PdEq of 2,463,000 ounces PGM plus Gold. The River Valley PGM-Copper-Nickel Sulphide mineralized zones remain open to expansion, and geophysics currently completed and drilling to commence mid July 2017 as part of our ongoing continued exploration.

In 2016, the Company acquired the River Valley extension property from Mustang Minerals which added approximately 4kms to the project’s mineralized strike length.

ABOUT NAM’S LITHIUM DIVISION

The Company has several Hard Rock Lithium Projects in the Winnipeg River Pegmatite Field, located in SE Manitoba. This Pegmatite Field hosts the world class Tanco Pegmatite that has been mined for Tantalum, Cesium and Spodumene (one of the primary Lithium ore minerals) in varying capacities, since 1969. Today, the Tanco Mine is focused on the mining of Pollucite (primary Cesium ore) and the production of Cesium Formate, a completion drilling fluid for the petroleum industry. NAM’s Lithium Projects are strategically situated in this prolific Pegmatite Field. Presently, NAM is the largest mineral claim holder in the Winnipeg River Pegmatite Field and is seeking JV partners to further develop the company’s Li division.

QUALIFIED PERSON

The contents contained herein that relate to Exploration Results or Mineral Resources is based on information compiled, reviewed or prepared by Carey Galeschuk, a consulting geoscientist for New Age Metals. Mr. Galeschuk is the Qualified Person as defined by National Instrument 43-101 and has reviewed and approved the technical content of this news release.

On behalf of the Board of Directors

“Harry Barr”

Harry G. Barr

Chairman and CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward Looking Statements: This release contains forward-looking statements that involve risks and uncertainties. These statements may differ materially from actual future events or results and are based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. In addition, forward-looking statements include statements in which the Company uses words such as “continue”, “efforts”, “expect”, “believe”, “anticipate”, “confident”, “intend”, “strategy”, “plan”, “will”, “estimate”, “project”, “goal”, “target”, “prospects”, “optimistic” or similar expressions. These statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others, the Company’s ability and continuation of efforts to timely and completely make available adequate current public information, additional or different regulatory and legal requirements and restrictions that may be imposed, and other factors as may be discussed in the documents filed by the Company on SEDAR (www.sedar.com), including the most recent reports that identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. The Company does not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Investors should not place undue reliance on forward-looking statements.

Tags: , , , , ,
Posted in All Recent Posts, New Age Metals | Comments Off on New Age Metals Commences 15,000 ft Drill Program at River Valley – Largest Underveloped PGM Project in Canada $PGM.ca

FEATURE: 7km’s of Gold Vault Strike Between 3 Gold Producers $OPW.ca

Posted by AGORACOM-JC at 4:34 PM on Monday, July 17th, 2017

Opw

WHY OPAWICA?

  • 7km’s of gold vault strike between 3 gold producers
  • In one of the largest gold producing regions in Canada
  • Adjoining to Ridgemont, Granada and Kinross Gold Producing Mines in Rouyn-Noranda Quebec
  • Bazooka properties cover 7 kilometres of the prolific CLLB
  • Cadilac-lardner lake fault system has produced Over 200M oz of GOLD

BAZOOKA EAST GOLD PROPERTY ‐ QUEBEC

Phase I drilling program consisted of five holes totalling 2,172 metres of drilling.

  • Hole 01 intersected a wide zone of gold mineralization approximately 185 metres east of a Lake Shore Gold Corp. (“LSG”) hole drilled in 2004 (BA-03-02A), which returned several narrow high grade gold intercepts with visible gold along with intermittent anomalous gold values.
  • In addition, drilling completed in 2011 by RT Minerals Corp. (“RTM”) intersected this favourable horizon (zone) about 50 metres east of current Opawica drilling. This historic hole intersected 17 metres of core length at 7.86 g/t Au (RTM June 21, 2011 press release).
  • With the 54.8 metre wide zone intersected in current drilling a further review of the historic LSG hole has resulted in the restating of the LSG hole at 1.68 g/t Au (uncut) (including 17 metres at 3.59 g/t Au) and 0.95 g/t (cut to 31 g/t Au) over 48 metres. The current Opawica hole and the historic LSG hole both contained fuchsite and arsenopyrite and are in close proximity to the Cadillac Larder Lake Break (“CLLB”).
  • Hole 02 in the current program intersected highly anomalous gold values (0.17 g/t Au) over the same zone for 39.9 metres. Hole 03 also intersected the same zone returning anomalous gold values (0.12 g/t Au) over 20.5 metres. Hole 04 also hit the same zone returning anomalous gold values and Hole 05 intersected the zone over a width of 65.5 metres containing highly anomalous gold values (0.24 g/t Au).

All of the above current and historic intervals are estimated at approximately 85% to 95% true widths. Assaying was completed by Swastika Laboratories Ltd. of Kirkland Lake, Ontario.An NI 43-101 technical report on the Bazooka property dated March 20, 2016

HISTORICAL RESULTS

BAZOOKA PROPERTY – EAST BOUNDARY

MCWATTERS GOLD PROPERTY

  • Bazooka and McWatters gold properties are located near Rouyn Noranda, Quebec, and are situated along the prolific Cadillac
    -Larder Lake Break (“CLLB”)
  • Company owns 100% interest in the Bazooka & McWatters properties Adjacent Bazooka and Bazooka West properties extend the Company’s strike length along the CLLB to approximately 7 km.
  • Kinross has signed a CDN $60 million definitive option agreementto purchase 100% of the adjacent Yorbeau Resources Inc. Rouyn Property (see Yorbeaupress release of October 25, 2016).

FACT SHEET

CORPORATE PRESENTATION

12 MONTH STOCK CHART

Tags: , , ,
Posted in AGORACOM Client Feature, All Recent Posts, Opawica Explorations Inc. | Comments Off on FEATURE: 7km’s of Gold Vault Strike Between 3 Gold Producers $OPW.ca

PyroGenesis Announces Receipt of CAN$445,950 Under Existing Military Contract; Plus CAN$300,000 of Warrants exercised $PYR.ca

Posted by AGORACOM-JC at 9:02 AM on Monday, July 17th, 2017

Pyr header 1

  • Further to its press release of January 10, 2017, wherein it was announced that the Company had signed two additional military contracts totaling approx. US$1.2MM (CAN$1.6MM)
  • Company has received US$367,982 (CAN$445,950) under one of these contracts.

MONTREAL, QUEBEC–(July 17, 2017) – PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX VENTURE:PYR)(OTCQB:PYRNF), a high tech company (the “Company” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma based systems and plasma torch products, is pleased to announce today that, further to its press release of January 10, 2017, wherein it was announced that the Company had signed two additional military contracts totaling approx. US$1.2MM (CAN$1.6MM), the Company has received US$367,982 (CAN$445,950) under one of these contracts.

The payment announced today is one of several payments received since January 10, 2017, by PyroGenesis totaling US$925,122 (CAN$1.2MM) under an original contract worth US$978,312 (CAN$1.25MM). The balance of approximately US$53K (CAN$68K) is expected to be received during Q3 2017.

Additionally, the Company announces today that CAN$300,000 of warrants have been exercised. “This exercise of warrants is timely,” said P. Peter Pascali, President and CEO of PyroGenesis. “We are currently looking beyond the ramp-up phase towards increasing production capacity ahead of our original expectations. This exercise of warrants, together with any future exercise of warrants and options, will enable us to implement plans to accelerate our original schedule to increase our production capacity of metal powders for the Additive manufacturing (3D Printing) industry. We are currently looking at ways to have up to three (3) additional powder production systems operating in 2018. Overall, to date, our metal powder production strategy is progressing far better than planned, and we are very pleased.”

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc. is the world leader in the design, development, manufacture and commercialization of advanced plasma processes. PyroGenesis provides engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Its core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Its operations are ISO 9001:2008 certified, and have been ISO certified since 1997. PyroGenesis is a publicly-traded Canadian company on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace (Ticker Symbol: PYRNF). For more information, please visit www.pyrogenesis.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTC Markets Group Inc. accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.

Rodayna Kafal
VP, Investor Relations and Communications
(514) 937-0002
[email protected] or [email protected]
www.pyrogenesis.com

Tags: , , , , ,
Posted in Featured, PyroGenesis Canada Inc. | Comments Off on PyroGenesis Announces Receipt of CAN$445,950 Under Existing Military Contract; Plus CAN$300,000 of Warrants exercised $PYR.ca

BOOOM! Patriots, Mets Amongst Pro Teams That Bought Cities In Overwatch Global ESports League. $GMBL.us

Posted by AGORACOM-JC at 3:33 PM on Wednesday, July 12th, 2017
  • Blizzard has announced major investment in its Overwatch League, the official home of Overwatch esports, first announced at last year’s Blizzcon.
  • Seven team slots have been acquired by organisations from both the traditional sports and esports worlds, as well as a couple of tech-focused entrepreneurs, with ESPN reporting a potential fee of $20 million per team.

“We’re not commenting on the price of the spot,” said Nate Nanzer, Commissioner of the Overwatch League when I spoke to him this week. “But we can talk a little bit about the terms of the relationship.

“I think one of the key differences in our structure is the local opportunity. There really hasn’t been a city-based, global league in this way. Not just in esports, but in traditional sports too, there hasn’t ever really been a league where Los Angeles plays Shanghai in the regular season.”

When a team owner purchases a position in the league, they also acquire the rights to a city of their choice. Boston, for example, has been picked up by Robert Kraft, the Chairman and CEO of the American football team, the New England Patriots.

His team will eventually have a home stadium in Boston, with all local revenues (up to an undisclosed figure) remaining with the team itself. On top of that, the team will have the option to host and monetise up to five amateur Overwatch League events in their home territory each year.

The other team owners include Jeff Wilpon, the COO of the New York Mets, who unsurprisingly nabbed New York as his team’s city of choice, as well as a couple of tech organisations based out of Shanghai and Seoul. There are also three esports-only teams, often referred to as ‘endemics’: Immortals (Los Angeles), Misfits Gaming (Miami-Orlando) and NRG Esports (San Francisco).

“I’m happy to announce that we have three endemic teams to reveal today, despite the fact that the internet says we don’t talk to endemics,” said Nanzer. “Obviously we’re also very excited about the traditional sports owners because they bring a lot of incredible history to the table: building generational fandom around their teams and great local expertise, which is important for our city-based, home and away structure.”

ow_league_2

The Commissioner.

A couple of weeks ago, Eurogamer published an article that questioned the current state of Overwatch esports, suggesting that since the announcement of the Overwatch League in November, very little has actually happened. More than that, its announcement in some ways had a damaging effect on the tournaments operating outside of the league itself.

“We wanted to make sure that when we spoke with our community next in a meaningful way, we had really important stuff to talk about,” said Nanzer when I questioned him on this. “Building a sports league from scratch is pretty hard and takes a lot of time.

“Blizzcon is obviously the best place ever for us to announce anything, but do I wish Blizzcon had been in March or April, instead of November? Sure.”

We’re still waiting on the league’s official start date, although we’ve been been told the first season will begin at some point this year. For the duration of that season, all matches will be played at a venue in Los Angeles, giving the seven team owners time to build up the necessary local infrastructure they’ll require going forwards.

During the league itself, matches will be played every Thursday, Friday and Saturday and we can apparently expect the match schedule soonâ„¢.

Source: http://www.eurogamer.net/articles/2017-07-12-blizzards-big-plan-for-overwatch-esports-allows-teams-to-buy-cities

Tags: , , , , , ,
Posted in All Recent Posts, Esports Entertainment Group, Esports Entertainment Group Inc., Featured | Comments Off on BOOOM! Patriots, Mets Amongst Pro Teams That Bought Cities In Overwatch Global ESports League. $GMBL.us

PyroGenesis Announces Receipt of $230,168 Contract for Support During Testing of its Chemical Warfare Agent Destruction System Using Real Chemical Warfare Agents $PYR.ca

Posted by AGORACOM-JC at 8:46 AM on Tuesday, July 11th, 2017

Pyr header 1

  • Received a CAN$230,168 contract to provide technical support during the next and final testing phase of its tactical Plasma Arc Chemical Warfare Agents Destruction System
  • Will now be tested using real chemical warfare agents

MONTREAL, QUEBEC–(July 11, 2017) – PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX VENTURE:PYR)(OTCQB:PYRNF), a high tech company (the “Company” or “PyroGenesis” or “PCI”) that designs, develops, manufactures and commercializes plasma based systems and plasma torch products, is pleased to announce today that, further to its press release of April 19, 2017, it has received a CAN$230,168 contract to provide technical support during the next and final testing phase (the “Final Testing Phase”) of its tactical Plasma Arc Chemical Warfare Agents Destruction System (“PACWADS” or the “System”) which will now be tested using real chemical warfare agents.

On April 19, 2017, the Company announced that it had, in coordination with the US-based Southwest Research Institute (SwRI), successfully completed long-duration performance tests using the Company’s System with surrogate chemical warfare agent material. These tests supported the Defense Advanced Research Projects Agency (DARPA) Agnostic Compact Demilitarization of Chemical Agents (ACDC) program and the results far exceeded minimum requirements with over 99.9999% destruction efficiency. The Final Testing Phase, which is expected to take approximately six (6) months, will be conducted using real chemical warfare agents at secure military facilities abroad, and is expected to confirm the results obtained at PyroGenesis’ facilities using surrogate chemical warfare agents.

“We are highly confident that our System will pass the Final Testing Phase particularly given the fact that we significantly exceeded the minimum requirements of 99.99% destruction efficiency using surrogates,” said Pierre Carabin, Chief Technology Officer of PyroGenesis. “As previously announced, our System demonstrated more than 99.9999% efficiency using surrogates which emulated destruction of such chemical warfare agents such as sarin (GB), soman (GD), and mustard (HD). This additional contract will allow PyroGenesis to support testing using real chemical warfare agents at a secure site.”

The System has already been shipped to a secure site and the Final Testing Phase begun. These tests are expected to be completed by the end of Q3 2017; however, this timeline is out of the Company’s control.

“If successful, PACWADS will be one of the few technologies in the world capable of destroying chemical warfare agents. We anticipate that such success will open the doors to additional opportunities; for example, the safe destruction of Ebola contaminated material in countries such as Liberia”, said Philippe Beaulieu, Senior Project Manager at PyroGenesis.

“A successfully developed System would safely destroy chemical warfare agent stockpiles onsite without having to transport these highly toxic chemicals to a remote location for processing, and although we would expect additional contracts resulting from a successful completion of the Final Testing Phase no indication has been given as to the size, if any, such procurement would entail,” said P. Peter Pascali, President and CEO of PyroGenesis. “The fact that our System is in the Final Testing Phase reflects the significant advances that we, at PyroGenesis, have achieved, and which we expect to continue to achieve in the area of defense and chemical warfare agent destruction. This only further solidifies our position within the US military as being the ‘go-to’ supplier of plasma-based solutions.”

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc. is the world leader in the design, development, manufacture and commercialization of advanced plasma processes. PyroGenesis provides engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Its core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Its operations are ISO 9001:2008 certified, and have been ISO certified since 1997. PyroGenesis is a publicly-traded Canadian company on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace (Ticker Symbol: PYRNF). For more information, please visit www.pyrogenesis.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTC Markets Group Inc. accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.

Rodayna Kafal
VP, Investor Relations and Communications
(514) 937-0002
[email protected] or [email protected]
www.pyrogenesis.com

Tags: , ,
Posted in Featured, PyroGenesis Canada Inc. | Comments Off on PyroGenesis Announces Receipt of $230,168 Contract for Support During Testing of its Chemical Warfare Agent Destruction System Using Real Chemical Warfare Agents $PYR.ca

Namaste Announces Record Breaking Sales of C$1.34M Representing 21.8% Month-On-Month Increase $N.ca

Posted by AGORACOM-JC at 8:49 AM on Monday, July 10th, 2017

Nlogo

  • Achieved record monthly sales and traffic for the month of June
  • Total unaudited sales as reported by the Company were C$1,349,545 in June 2017
  • Compared to C$1,108,034 in May 2017, a 21.8% increase.

VANCOUVER, British Columbia, July 10, 2017 — Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRANKFURT:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that it has achieved record monthly sales and traffic for the month of June. The total unaudited sales as reported by the Company (including shipping revenues and after discounts and refunds) were C$1,349,545 in June 2017 compared to C$1,108,034 in May 2017, a 21.8% increase.

The month-on-month increase in revenue was achieved across the large network of sites operated by Namaste which all showed higher conversion rates. The increase in revenue is particularly pleasing as typically revenue is soft during the summer months. Namaste Vapes and Everyonedoesit showed good progress in conversion rates and average order value which were drivers of revenue growth. Australian Vaporizers benefited from an already high conversion rate which increased to 4.5% for the month.

The table below displays a revenue breakdown for Namaste’s various sales channels.

Revenues – June 2017 (C$)
Channels   6,942
Distribution Goods   143,437
Dropshipping   18,972
EDIT   191,500
Green Vapes   17,273
Namaste   547,459
Australian Vaporizers   423,961
Total revenues     1,349,545
Below are gross sales of the major sites operated by the Company. Revenues below do not include shipping revenues and are before discounts and refunds.
Selected operating data e-Commerce June 2017 in C$    
  traffic conversion orders  basket price  gross revenues
Namaste 94,139 1.96 % 1,845 $   278 $   513,827
Australian Vaporizers 45,040 4.50 % 2,026 $   182 $   367,766
EDIT 247,717 0.87 % 2,148 $   94 $   201,134
GreenVapes 3,479 1.47 % 51 $   303 $   15,469
Total   390,375 1.55 %   6,070 $    181 $    1,098,195

Namaste has implemented proprietary machine learning algorithms on several of its major sites that adjust website content and product listings ‘on-the-fly’ based on user behavior. These sites have seen substantial increases in conversion rates as a result and Namaste plans on launching the same technology throughout their platform.

At the end of June the Company granted 1,725,000 options to staff and consultants. The options will vest quarterly over a period of two years and are exercisable for five years at an exercise price of $0.25.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments: “We’re very excited to see amazing results in June sales due to of all the hard work from our management team in implementing innovative strategies to increase sales organically. The implementation of machine learning to our platform has had immediate positive results. We expect to see similar results once this technology is launched throughout our platform. We look forward to continued growth as well as expansion into new markets and product categories.”

About Namaste Technologies Inc.

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 ecommerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.vaporseller.com

www.everyonedoesit.com

www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Contact:
Sean Dollinger
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Tags: , , , , ,
Posted in Featured, Namaste Technologies Inc. | Comments Off on Namaste Announces Record Breaking Sales of C$1.34M Representing 21.8% Month-On-Month Increase $N.ca

Tetra Bio-Pharma Strengthens its Position on Bringing Marijuana to Patients in a Form Acceptable to Health Care Professionals $TBP.ca

Posted by AGORACOM-JC at 9:05 AM on Wednesday, July 5th, 2017

Tbp large

  • Strengthened its position on bringing marijuana to patients in the form of a prescription drug
  • Has become a world leader in the field of cannabis drug development and its PPP001 dried cannabis drug was covered in the Global Pain Management Drugs Market analysis report published by Azoth Analytics in May 2017

OTTAWA, ONTARIO–(July 5, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), today announced that it has strengthened its position on bringing marijuana to patients in the form of a prescription drug. Tetra has become a world leader in the field of cannabis drug development and its PPP001 dried cannabis drug was covered in the Global Pain Management Drugs Market analysis report published by Azoth Analytics in May 2017. According to this report, Tetra is the only company developing dried marijuana as a drug.

One in five Canadians will live with pain in their lifetime and one in two will be affected by cancer. Canadian courts have ruled in favor of patients wanting access to marijuana for relief. In response to these decisions, the Canadian government has implemented the Access to Cannabis for Medical Purposes Regulations (ACMPR) to help bring marijuana to patients. Canada’s Prime Minister has been very favorable in bringing marijuana to patients but it will be up to corporations to step in and adhere to the Canadian Food and Drug regulations to bring marijuana medications to patients. Tetra is a world leader in the drug development field of cannabis-based medications and is paving the road to become the first company to commercialize a dried marijuana product as a drug in North America.

“Canadian’s are entitled to access to marijuana to treat their pain or its co-morbidities. It is not a question of social standing or a judgement if the act of ‘smoking’ is acceptable for patients. It is a fundamental right to have access to a botanical drug that can effectively allow patients to have a better quality of life,” commented Dr. Guy Chamberland, CSO of Tetra Bio-Pharma. “There is sufficient evidence suggesting that smoking marijuana is an adequate medication to help relieve pain and improve a patient’s well-being. Both of these are important aspects to offering effective therapies to patients. The challenge has been addressing quality and safety issues to meet the standards of a drug.”

Over the years our society has inherited an image that ‘smoking’ or ‘vaporizing’ is not associated with a healthy approach to health care. According to the expert committee on the Health Effects of Marijuana (National Academies Press, 2017), ‘smoking cannabis does not increase the risk for certain cancers (i.e., lung, head and neck)’. In addition, cancer patients typically consume an amount of dried marijuana per day, in dry weight, that is less than 1 tobacco cigarette, without the paper, per day. The significantly reduced amount of smoke per day is one of the explanations supporting that smoking marijuana does not increase the risk for these cancers. That said, these are effective routes of delivering a complex botanical medication. “Society has to focus on caring for all patients living with pain not just those that want a different dosage form,” commented Dr. Chamberland. He added, “In fact our challenge is to characterize the safety and efficacy of this therapy, ensure lot-to-lot quality, provide adequate risk information to health professionals, demonstrate the safety and efficacy so that physicians can adequately assess the potential efficacy and safety for their patient, and actively pursue more tolerable dosage forms to offer these innovative cannabis therapies to patients. In the end, a patient’s desire to smoke marijuana for relief has to be defended by Canadian courts and politicians. We live in a democratic society and we have to care for everyone.”

“Tetra undertook the development of PPP001 as a first prescription marijuana drug. The company is preparing its phase 3 trial in cancer patients and will assess the safety and efficacy using both the titanium pipe and vaporizer delivery systems. From Day 1, Tetra was dedicated to characterizing the safety and tolerability of consuming medical marijuana by smoking. Tetra also adopted the firm position of working transparently with regulators because the corporation believed it is important to bring marijuana, as traditionally used, to patients. Tetra will continue to work with provincial and federal governments, including physician and pharmacist professional corporations, to help address issues associated with the development and commercialization of a first prescription medical marijuana drug.”

“Tetra already works closely with Health Canada through the regulatory processes in place for the development of drugs and controlled substances,” commented Dr. Chamberland. He added that, “Tetra was working closely with the province of New Brunswick whom from Day 1 was very active in preparing for the eventual legalization of marijuana in Canada. Tetra is working with physician and pharmacist professional associations/corporations and will be working closely with these health professionals as the company prepares for its Phase 3 trial and the eventual commercialization of the first dried marijuana drug.”

“Tetra has performed safety, pharmacokinetic and cognitive function studies in healthy volunteers. The corporation has characterized the safety of consuming marijuana and understands what the potential risks are to consumers and patients. This information will be made available by Tetra to Health Canada and to other government departments on request. We believe that this safety data provides a clear and accurate picture of what happens to people that smoke marijuana recreationally,” commented Dr. Chamberland. “We believe it is our responsibility to provide this information to regulators to help pave the road for the Trudeau government’s legalization.”

In addition, Tetra will use its clinical knowledge from its Phase 1 and Safety clinical studies to implement effective and secure patient care programs. This includes working with independent professional organizations to transfer its clinical risk information and ensure that these groups provide continued medical education to their health professionals. Dr. Chamberland commented, “Launching the first dried marijuana drug in Canada brings a responsibility of ensuring that all safety risks are communicated to health professionals to ensure the well-being of consumers. No body wants another fentanyl-type crisis; all we want is for patients to obtain relief and an improved quality of life when consuming marijuana that is of the same quality as any other prescription medication.”

“Tetra will be actively pursuing the development and commercialization of PPP001 to remain a world leader in the field of cannabis medicine,” commented Andre Rancourt, CEO of Tetra Bio-Pharma. “We are dedicated to working with distributors and pharmaceutical companies interested in bringing medical marijuana as a prescription drug around the world. We are focusing on bringing to patients what the Supreme Court of Canada ruled was their right: access to marijuana.”

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
[email protected]

Tags: , , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma Strengthens its Position on Bringing Marijuana to Patients in a Form Acceptable to Health Care Professionals $TBP.ca

FEATURE: Monarques Gold (TSX-V: MQR) Flagship Croinor Gold Mine Has Great Potential To Become A Producer $MQR.ca

Posted by AGORACOM-JC at 10:11 AM on Thursday, June 29th, 2017

Monarquesgold hub large

Why Monarques Gold?

  • Flagship Croinor Gold Mine Has Great Potential To Become A Producer
  • Company Is Well Financed, Including $9 Million In Credits From Quebec Government
  • Hole CR-17-532 intersected 6.96 g/t Au over 15 metres (Read Release)
  • Including 17.1 g/t Au over 5.9 metres
  • Recently acquired 750 ton-per-day Beacon mill
  • Major Shareholders include: Rob McEwen and Nemaska Lithium

Croinor Gold Property

Flagship project at the prefeasibility stage

  • 100% interest in the Croinor Gold property, a gold mine project that is currently at the prefeasibility stage
  • Property consists of one mining lease and two non-contiguous blocks of claims for a total of 335 claims over a 151 km² area. A 1.5% NSR is applicable on the mining lease and only 44 claims.
  • Drilling program will test a diorite-hosted gold-bearing zone that returned grades of up to 38.7 g/t Au over 3.8 metres in historical drilling (see release)

WATCH OUR CORPORATE VIDEO

Check Out Croinor Gold
Prefeasability Study

Simkar Gold Property

NI 43-101 Gold Resource 20 km from Val-d’Or

  • 100% interest in the Simkar Gold property
  • located 20 kilometres east of Val-d’Or, in the heart of the Abitibi Greenstone Belt.
  • Comprised of two mining concessions and 15 claims covering an area of 5 km², and is subject to a 1.5% NSR.
  • NI 43-101 (click here)

The Simkar Gold property is the result of a merger of the Simkar and Texsol properties. The transaction was announced by way of press release on June 26, 2014.

Regcourt Gold Property – Val d’Or

  • 100% interest in the Regcourt Gold property
  • Property is located at the eastern end of the Val-d’Or gold mining camp, some 30 km east of Val-d’Or, and is easily accessible via Route 117.
  • Consists of 94 claims covering an area of 38 km2 near the centre of the western border of Vauquelin Township
  • Property is subject to a 1.5% and 2.5 % NSR.

 

12 Month Stock Chart

Tags: , , ,
Posted in AGORACOM Client Feature, All Recent Posts, Monarques Gold | Comments Off on FEATURE: Monarques Gold (TSX-V: MQR) Flagship Croinor Gold Mine Has Great Potential To Become A Producer $MQR.ca

« Older Entries
Newer Entries »